HROW β Harrow Inc Β· catalysts, narrative & risks
Company Snapshot
Harrow, Inc. (Nasdaq: HROW) is a leading North American provider of ophthalmic disease management solutions, with a portfolio covering conditions affecting both the front and back of the eye (dry eye disease, wet/neovascular AMD, cataracts, refractive errors, glaucoma, and retinal diseases) [3], [5]. It operates through branded pharmaceuticals and ImprimisRx, its ophthalmology-focused compounding business [10]. (Note: some aggregators render the name as "Harrow Health, Inc.") [11]. The data types relevant to covering this stockβpress releases, analyst opinions, earnings transcripts, and price dataβare exactly the unstructured and structured inputs that modern equity-analysis frameworks draw upon [LIB-1], [LIB-2].
Key Recent Catalysts (last ~1β3 months)
AI-assisted research from the K3vl4r desk β not personalized investment advice. More research β